What happened to the missing tablets is a matter of conjecture.
ii) Counting the remaining tablets: The caregiver records the number of tablets or capsules remaining and evaluates adherence by considering a missed tablet or capsule as a tablet or capsule absorbed.
However, some women missed tablets and did not recognise that this could reduce the efficacy of the treatment.
We found that women seek to be adherent but some will miss tablets without realising the potential consequences.
Subjects answered a question regarding the prescribed numbers of aminosalicylate tablets and missed tablets; the number of tablets was converted to a dose.
Other women believed they were fully adherent and had implemented routines to help them remember, but admitted they sometimes missed tablets.
Factors that may have also affected the results include poor compliance with bisphosphonate therapy, although the ARBI trial included compliance assessment at each follow-up visit and missed tablets were reported by <10% of the study patients.
Compliance to treatment was confirmed during the interview in each patient's follow-up visit; occasionally, missed tablets of either anastrozole or risedronate were reported by less than 10% of the patients under study treatment.
All participants were instructed to record the onset of any adverse events in a personal daily document, with the specific indication of their characteristics (severity, duration, and possible cause effect relationship with the drug administration), the number of missed tablets, and any changes in the diet, physical exercise, or weight.
The compliance results were presented as: "excellent" for eating all tablets, "good" for only missing 1∼5 tablets, "moderate" for missing 6∼10 tablets, and "poor" for missing more than 10 tablets.
I will have a fit if I'm still taking my tablet but, if I miss a tablet, I'm still going to have a fit.
